☰

Alexander T. Pearson, Ph.D. - Publications

Affiliations: 
2010 University of Rochester, Rochester, NY 
Area:
Statistics
Tree Info Similar researchers PubMed Report error

61 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Goldberg M, Manzi A, Conway P, Cantin S, Mishra V, Singh A, Pearson AT, Goldberg ER, Goldberger S, Flaum B, Hasina R, London NR, Gallia GL, Bettegowda C, O'Neill SE, et al. A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer. Nature Communications. 13: 4829. PMID 35977936 DOI: 10.1038/s41467-022-31859-3  0.302
2021 Broner EC, Trujillo JA, Korzinkin M, Subbannayya T, Agrawal N, Ozerov IV, Zhavoronkov A, Rooper L, Kotlov N, Shen L, Pearson AT, Rosenberg AJ, Savage PA, Mishra V, Chatterjee A, et al. Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology. 11: 677051. PMID 34336664 DOI: 10.3389/fonc.2021.677051  0.305
2021 Andrade NP, Warner KA, Zhang Z, Pearson AT, Mantesso A, Guimaraēs DM, Altemani A, Mariano FV, Nunes FD, Nör JE. Survival of salivary gland cancer stem cells requires mTOR signaling. Cell Death & Disease. 12: 108. PMID 33479203 DOI: 10.1038/s41419-021-03391-7  0.317
2021 Andrade NP, Warner KA, Zhang Z, Pearson AT, Mantesso A, Guimaraēs DM, Altemani A, Mariano FV, Nunes FD, Nör JE. Survival of salivary gland cancer stem cells requires mTOR signaling. Cell Death & Disease. 12: 108. PMID 33479203 DOI: 10.1038/s41419-021-03391-7  0.317
2020 Howard FM, Kochanny S, Koshy M, Spiotto M, Pearson AT. Machine Learning-Guided Adjuvant Treatment of Head and Neck Cancer. Jama Network Open. 3: e2025881. PMID 33211108 DOI: 10.1200/Jco.2020.38.15_Suppl.6567  0.364
2020 Kolbe AR, Bendall ML, Pearson AT, Paul D, Nixon DF, Pérez-Losada M, Crandall KA. Human Endogenous Retrovirus Expression Is Associated with Head and Neck Cancer and Differential Survival. Viruses. 12. PMID 32872377 DOI: 10.3390/V12090956  0.372
2020 Bryan DS, Stack M, Krysztofiak K, Cichoń U, Thomas DG, Surcel A, Schiffhauer ES, Beckett MA, Khodarev NN, Xue L, Poli EC, Pearson AT, Posner MC, Robinson DN, Rock RS, et al. 4-Hydroxyacetophenone modulates the actomyosin cytoskeleton to reduce metastasis. Proceedings of the National Academy of Sciences of the United States of America. PMID 32848073 DOI: 10.1073/Pnas.2014639117  0.388
2020 Echle A, Grabsch HI, Quirke P, van den Brandt PA, West NP, Hutchins GGA, Heij LR, Tan X, Richman SD, Krause J, Alwers E, Jenniskens J, Offermans K, Gray R, Brenner H, ... ... Pearson AT, et al. Clinical-grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning. Gastroenterology. PMID 32562722 DOI: 10.1053/J.Gastro.2020.06.021  0.319
2020 Facompre ND, Rajagopalan P, Sahu V, Pearson AT, Montone KT, James CD, Gleber-Netto FO, Weinstein GS, Jalaly J, Lin A, Rustgi AK, Nakagawa H, Califano JA, Pickering CR, White EA, et al. Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models. International Journal of Cancer. PMID 32478869 DOI: 10.1002/Ijc.33125  0.359
2020 Xavier JB, Young VB, Skufca J, Ginty F, Testerman T, Pearson AT, Macklin P, Mitchell A, Shmulevich I, Xie L, Caporaso JG, Crandall KA, Simone NL, Godoy-Vitorino F, Griffin TJ, et al. The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends in Cancer. 6: 192-204. PMID 32101723 DOI: 10.1016/J.Trecan.2020.01.004  0.389
2020 Nazari F, Oklejas AE, Nör JE, Pearson AT, Jackson TL. In silico models accurately predict in vivo response for IL-6 blockade in head and neck cancer. Cancer Research. PMID 32041834 DOI: 10.1158/0008-5472.Can-19-1846  0.456
2020 Freeman ZT, Nirschl TR, Hovelson DH, Johnston RJ, Engelhardt JJ, Selby MJ, Kochel CM, Lan RY, Zhai J, Ghasemzadeh A, Gupta A, Skaist AM, Wheelan SJ, Jiang H, Pearson AT, et al. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. The Journal of Clinical Investigation. PMID 32015231 DOI: 10.1172/Jci128672  0.397
2020 Shen CJ, Jameson KL, Weiss J, Hackman T, Dixon R, Akulian JA, Pearson AT, Frakes J, Said P, Seiwert TY. NANORAY-1100: A phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with anti-PD-1 therapy. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.5_Suppl.Tps86  0.36
2020 Shen C, Frakes J, Weiss J, Caudell JJ, Hackman TG, Akulian JA, El-Haddad G, Hu Y, Dixon R, Pearson AT, Barsoumian HB, Cortez MA, Jameson KL, Said P, Welsh JW, et al. Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps3173  0.346
2020 Rosenberg A, Kochanny S, Dolezal J, Wang C, Chen H, Kather JN, Pearson AT. Prediction of histologic and molecular subsets of soft tissue sarcoma using deep learning. Journal of Clinical Oncology. 38: e23529-e23529. DOI: 10.1200/Jco.2020.38.15_Suppl.E23529  0.312
2020 Rosenberg A, Agrawal N, Pearson AT, Seiwert TY, Gooi Z, Blair EA, Cursio J, Howard A, Chin J, Foster CC, Kochanny S, Lingen MW, Haraf DJ, Vokes EE. Dose and volume de-escalation for HPV-associated oropharyngeal cancer: Long-term follow-up of the OPTIMA trial. Journal of Clinical Oncology. 38: 6575-6575. DOI: 10.1200/Jco.2020.38.15_Suppl.6575  0.315
2020 Cohen RB, Bauman JR, Salas S, Colevas AD, Even C, Cupissol D, Posner MR, Lefebvre G, Saada-Bouzid E, Bernadach M, Seiwert TY, Pearson AT, Calmels F, Zerbib R, Andre P, et al. Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors. Journal of Clinical Oncology. 38: 6516-6516. DOI: 10.1200/Jco.2020.38.15_Suppl.6516  0.376
2020 Facompre ND, Rajagopalan P, Pearson AT, Montone KT, James CD, Gleber-Netto FO, Nakagawa H, White EA, Rustgi AK, Califano JA, Pickering CR, Windle B, Morgan IM, Gimotty PA, Basu D. Abstract A01: HPV+ oral cancer PDXs identify prognostic utility for E2F target gene expression and mutation burden Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Aacrahns19-A01  0.36
2020 Rosenberg A, Agrawal N, Pearson A, Seiwert T, Gooi Z, Blair E, Spiotto M, Jones M, Haraf D, Vokes E. Low risk HPV associated oropharyngeal squamous cell carcinoma treated with induction chemoimmunotherapy followed by TORS or radiotherapy International Journal of Radiation Oncology*Biology*Physics. 106: 1123. DOI: 10.1016/J.Ijrobp.2019.11.342  0.319
2020 Dolezal J, Kather JN, Kochanny S, Schulte J, Patel A, Munyampirwa B, Morin S, Srisuwananukorn A, Cipriani N, Basu D, Pearson A. Deep learning detects actionable molecular and clinical features directly from head/neck squamous cell carcinoma histopathology slides International Journal of Radiation Oncology Biology Physics. 106: 1165. DOI: 10.1016/J.Ijrobp.2019.11.157  0.311
2019 Schubert AD, Channah Broner E, Agrawal N, London N, Pearson A, Gupta A, Wali N, Seiwert TY, Wheelan S, Lingen M, Macleod K, Allen H, Chatterjee A, Vassiliki S, Gaykalova D, et al. Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma. Cancer Letters. PMID 31830557 DOI: 10.1016/J.Canlet.2019.12.006  0.316
2019 Kather JN, Pearson AT, Halama N, Jäger D, Krause J, Loosen SH, Marx A, Boor P, Tacke F, Neumann UP, Grabsch HI, Yoshikawa T, Brenner H, Chang-Claude J, Hoffmeister M, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nature Medicine. PMID 31160815 DOI: 10.1038/S41591-019-0462-Y  0.354
2019 Cipriani NA, Lusardi JJ, McElherne J, Pearson AT, Olivas AD, Fitzpatrick C, Lingen MW, Blair EA. Mucoepidermoid Carcinoma: A Comparison of Histologic Grading Systems and Relationship to MAML2 Rearrangement and Prognosis. The American Journal of Surgical Pathology. PMID 31021855 DOI: 10.1097/Pas.0000000000001252  0.331
2019 Pearson AT, Sweis RF. Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer. Jama Oncology. PMID 30896751 DOI: 10.1001/Jamaoncol.2019.0130  0.343
2019 Basu D, Facompre ND, Gimotty PA, Rajagopalan P, Sahu V, Pearson AT, Califano JA, Netto F, Pickering CR. Identifying adverse molecular features of HPV+ head and neck cancers using patient-derived models. Journal of Clinical Oncology. 37: 6057-6057. DOI: 10.1200/Jco.2019.37.15_Suppl.6057  0.336
2019 Hatogai K, Kim D, Zha Y, Steinberg GD, Pearson AT, Gajewski TF, Sweis RF. Abstract 1093: Multichannel immunofluorescence imaging to assess the immune composition of tumor microenvironment in bladder cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1093  0.349
2019 Shen C, Jameson K, Weiss J, Hackman T, Corum D, Akulian JA, Dixon R, Pearson A, Frakes J, Said P, Miraoui H, Baskin-Bey E, Seiwert T. 126TiP a Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz451.034  0.346
2018 Warner KA, Oklejas AE, Pearson AT, Zhang Z, Wu W, Divi V, Rodriguez-Ramirez C, Castilho RM, Polverini PJ, Nör JE. UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line. Oral Oncology. 87: 21-28. PMID 30527239 DOI: 10.1016/J.Oraloncology.2018.10.012  0.304
2018 Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, Nör F, Zhang Z, Kerk S, Kulkarni A, Helman JI, Brenner JC, Wicha MS, Wang S, Nör JE. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30498096 DOI: 10.1158/1078-0432.Ccr-17-2730  0.384
2018 Coffman LG, Pearson AT, Frisbie LG, Freeman Z, Christie E, Bowtell DD, Buckanovich RJ. Ovarian carcinoma-associated mesenchymal stem cells arise from tissue-specific normal stroma. Stem Cells (Dayton, Ohio). PMID 30353617 DOI: 10.1002/Stem.2932  0.335
2018 Nazari F, Pearson AT, Nör JE, Jackson TL. A mathematical model for IL-6-mediated, stem cell driven tumor growth and targeted treatment. Plos Computational Biology. 14: e1005920. PMID 29351275 DOI: 10.1371/Journal.Pcbi.1005920  0.389
2018 Kochanny S, Foster CC, Khattri A, Acharya R, Dekker A, Tan YC, Klema E, Brisson RJ, Saloura V, Pearson AT, Vokes EE, Leidner RS, Mehanna HM, Seiwert TY. Association of low serum albumin concentration with reduced overall survival for patients with metastatic head and neck cancer receiving anti-programmed death receptor-1 therapy. Journal of Clinical Oncology. 36: 6057-6057. DOI: 10.1200/Jco.2018.36.15_Suppl.6057  0.338
2018 Foster CC, Kochanny S, Khattri A, Acharya R, Dekker A, Tan YC, Klema E, Brisson RJ, Saloura V, Pearson AT, Vokes EE, Leidner RS, Mehanna HM, Seiwert TY. Association of a baseline neutrophil-to-lymphocyte ratio (NLR) with progression-free and overall survival in head and neck cancer patients receiving anti-PD-1 therapy. Journal of Clinical Oncology. 36: 6038-6038. DOI: 10.1200/Jco.2018.36.15_Suppl.6038  0.394
2018 Foster CC, Kochanny S, Khattri A, Acharya R, Dekker A, Tan YC, Klema E, Brisson RJ, Saloura V, Pearson AT, Vokes EE, Leidner RS, Mehanna HM, Seiwert TY. Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy. Journal of Clinical Oncology. 36: 6014-6014. DOI: 10.1200/Jco.2018.36.15_Suppl.6014  0.37
2018 Freeman ZT, Hovleson DH, Pearson AT, Zhai J, Ghasemzadeh A, Nirschl TR, Jiang H, Tomlins SA, Drake CG. Abstract LB-118: A conserved checkpoint molecule signature offers novel targets for tumor specific regulatory T cell manipulation Immunology. DOI: 10.1158/1538-7445.Am2018-Lb-118  0.31
2018 Nazari F, Oklejas AE, Nör JE, Pearson AT, Jackson TL. Abstract 925: In silico models accurately predict in vivo response for IL-6 blockade in head and neck cancer Cancer Research. 78: 925-925. DOI: 10.1158/1538-7445.Am2018-925  0.401
2017 Pearson AT, Ingram P, Bai S, O'Hayer P, Chung J, Yoon E, Jackson T, Buckanovich RJ. Sampling from single-cell observations to predict tumor cell growth in-vitro and in-vivo. Oncotarget. 8: 111176-111189. PMID 29340046 DOI: 10.18632/Oncotarget.22693  0.41
2017 Kim HS, Chen YC, Nör F, Warner KA, Andrews A, Wagner VP, Zhang Z, Zhang Z, Martins MD, Pearson AT, Yoon E, Nör JE. Endothelial-derived interleukin-6 induces cancer stem cell motility by generating a chemotactic gradient towards blood vessels. Oncotarget. 8: 100339-100352. PMID 29245982 DOI: 10.18632/Oncotarget.22225  0.399
2017 Manohar PM, Sapir E, Bellile E, Swiecicki PL, Pearson AT, Prince ME, Shuman AG, Bradford CR, Chepeha DB, Wolf GT, Eisbruch A, Worden FP, Spector ME. Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 194599817722948. PMID 28809131 DOI: 10.1177/0194599817722948  0.343
2016 Bai S, Ingram P, Chen YC, Deng N, Pearson A, Niknafs Y, O'Hayer P, Wang Y, Zhang ZY, Boscolo E, Bischoff J, Yoon E, Buckanovich RJ. EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells. Cancer Research. 76: 6396-6409. PMID 27803106 DOI: 10.1158/0008-5472.Can-16-0225  0.438
2016 Kerk S, Finkel K, Pearson AT, Warner K, Nor F, Zhang Z, Wagner VP, Vargas PA, Wicha MS, Hurt E, Hollingsworth RE, Tice DA, Nor JE. 5T4-targeted therapy ablates cancer stem cells and prevents recurrence of head and neck squamous cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27780858 DOI: 10.1158/1078-0432.Ccr-16-1834  0.443
2016 Nor F, Warner K, Zhang Z, Acasigua G, Pearson AT, Kerk S, Helman JI, Sant'Ana Filho M, Wang S, Nor JE. Therapeutic inhibition of the MDM2-p53 interaction prevents recurrence of adenoid cystic carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27550999 DOI: 10.1158/1078-0432.Ccr-16-1235  0.372
2016 Swiecicki PL, Bellile E, Sacco AG, Pearson AT, Taylor JM, Jackson TL, Chepeha DB, Spector ME, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Sukari A, Wolf GT, et al. A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Investigational New Drugs. PMID 27225873 DOI: 10.1007/S10637-016-0364-5  0.38
2016 Pearson AT, Jackson TL, Nör JE. Modeling head and neck cancer stem cell-mediated tumorigenesis. Cellular and Molecular Life Sciences : Cmls. PMID 27151511 DOI: 10.1007/S00018-016-2226-X  0.416
2016 Warner K, Nor F, Acasigua G, Martins M, Zhang Z, McLean SA, Spector ME, Chepeha D, Helman JI, Wick M, Moskaluk CA, Castilho RM, Pearson AT, Wang S, Nor JE. Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26936915 DOI: 10.1158/1078-0432.Ccr-15-1698  0.31
2016 Kim HS, Pearson AT, Nör JE. Isolation and Characterization of Cancer Stem Cells from Primary Head and Neck Squamous Cell Carcinoma Tumors. Methods in Molecular Biology (Clifton, N.J.). 1395: 241-9. PMID 26910078 DOI: 10.1007/978-1-4939-3347-1_14  0.43
2016 Pearson AT, Finkel KA, Warner KA, Nör F, Tice D, Martins MD, Jackson TL, Nör JE. Patient-derived xenograft (PDX) tumors increase growth rate with time. Oncotarget. PMID 26783960 DOI: 10.18632/Oncotarget.6919  0.383
2016 Smyth EC, Turner NC, Pearson A, Peckitt C, Chau I, Watkins DJ, Starling N, Rao S, Gillbanks A, Kilgour E, Sumpter KA, Smith NR, Cutts R, Rooney C, Thomas AL, et al. Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results. Journal of Clinical Oncology. 34: 154-154. DOI: 10.1200/Jco.2016.34.4_Suppl.154  0.388
2016 Kerk S, Pearson AT, Warner K, Zhang Z, Finkel K, Helman J, Hurt E, Hollingsworth R, Tice D, Nor J. 5T4 oncofetal antigen as a prognostic marker and target for treatment in head and neck squamous cell carcinoma. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E17516  0.357
2016 Pearson AT, Ingram P, Bai S, Yoon E, Jackson T, Buckanovich RJ. Abstract 2705: A computational algorithm to predict tumor growth and cancer stem cell proportion in-vitro and in-vivo from single-cell observations Cancer Research. 76: 2705-2705. DOI: 10.1158/1538-7445.Am2016-2705  0.377
2016 Pearson A, Finkel KA, Warner KA, Nor F, Tice DA, Martins MD, Jackson TL, Nor JE. Abstract 2380: Head and neck patient derived xenografts acquire histopathological and growth rate changes over increasing passages Cancer Research. 76: 2380-2380. DOI: 10.1158/1538-7445.Am2016-2380  0.377
2015 Adams A, Warner K, Pearson AT, Zhang Z, Kim HS, Mochizuki D, Basura G, Helman J, Mantesso A, Castilho RM, Wicha MS, Nör JE. ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas. Oncotarget. 6: 26633-50. PMID 26449187 DOI: 10.18632/Oncotarget.5782  0.364
2015 Mochizuki D, Adams A, Warner KA, Zhang Z, Pearson AT, Misawa K, McLean SA, Wolf GT, Nör JE. Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma. Oncotarget. 6: 22822-35. PMID 26287605 DOI: 10.18632/Oncotarget.4477  0.409
2015 Acasigua GA, Warner KA, Nör F, Helman J, Pearson AT, Fossati AC, Wang S, Nör JE. BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma. Oral Oncology. PMID 26121939 DOI: 10.1016/J.Oraloncology.2015.06.004  0.333
2015 Scheier B, Pearson AT, Wilfong JM, Baker LH. Symptom assessment in patients with cancer of unknown primary site. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E20696  0.312
2015 Smyth EC, Turner NC, Peckitt C, Pearson A, Brown G, Chua S, Gillbanks A, Johnston SRD, Tarazona N, Cutts R, Kilgour E, Rooney C, Smith NR, Sumpter KA, Ajaz MA, et al. Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. Journal of Clinical Oncology. 33: 2508-2508. DOI: 10.1200/Jco.2015.33.15_Suppl.2508  0.331
2015 Asghar U, Herrera-Abreu MT, Cutts R, Babina I, Pearson A, Turner NC. Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition. Journal of Clinical Oncology. 33: 11098-11098. DOI: 10.1200/Jco.2015.33.15_Suppl.11098  0.309
2015 Babina I, Pearson A, Cutts R, Smyth E, Ning J, Swain A, Cunningham D, Turner NC. Abstract C37: Molecular determinants of sensitivity and resistance to FGFR inhibition in FGFR2-amplified gastric cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C37  0.4
2012 Sweis RF, Grivas P, Pearson AT, Day KC, Day ML, Hussain M. Expression of MET and HGF in bladder cancer tumorigenesis and invasion. Journal of Clinical Oncology. 30: 4573-4573. DOI: 10.1200/Jco.2012.30.15_Suppl.4573  0.335
2011 Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC, Natrajan R, Reynolds AR, Reis-Filho JS, Ashworth A, Turner NC. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5275-86. PMID 21712446 DOI: 10.1158/1078-0432.Ccr-10-2727  0.363
2010 Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Research. 70: 2085-94. PMID 20179196 DOI: 10.1158/0008-5472.Can-09-3746  0.367
Show low-probability matches.